SCHEMBL2679294

SCHEMBL2679294

COc1ccc(C(=O)Nc2n[nH]c3c2CN(S(=O)(=O)c2cccnc2)CC3(C)C)c(N)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB4 P30926 1/20 0.43
CHRNA3 P32297 1/20 0.43
LMNA P02545 2/20 0.42
CDK2 P24941 4/20 0.41
CCNA2 P20248 3/20 0.41
CCNA1 P78396 3/20 0.41
MEN1 O00255 1/20 0.40
POLB P06746 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NTRK1 P04629 1/20 0.40
USP2 O75604 3/20 0.39
USP8 P40818 3/20 0.39
CCNE2 O96020 1/20 0.38
CCNE1 P24864 1/20 0.38
GSK3B P49841 1/20 0.38
PIK3CG P48736 2/20 0.36
TSHR P16473 1/20 0.36
CHRNB2 P17787 1/20 0.36
CHRNA4 P43681 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2679291 0.92 CHRNB4 (0.42) CHRNB4CHRNA3LMNACDK2CCNA2
SCHEMBL2676623 0.88 CDK2 (0.44) CHRNB4CHRNA3CDK2CCNA2CCNA1
SCHEMBL2679281 0.88 CDK2 (0.41) CDK2CCNA2CCNA1POLBSMN1; SMN2
SCHEMBL2678481 0.87 IGF1R (0.43) CDK2CCNA2CCNA1NTRK1CCNE1
SCHEMBL1888534 0.87 IGF1R (0.46) CHRNB4CHRNA3LMNACDK2CCNA2
SCHEMBL2677972 0.85 NTRK1 (0.42) CDK2CCNA2CCNA1KMT2ASMN1; SMN2
SCHEMBL2678969 0.85 MET (0.47) CHRNB4CHRNA3LMNACDK2CCNA2
SCHEMBL2676622 0.84 CDK2 (0.44) CHRNB4CHRNA3CDK2CCNA2CCNA1
SCHEMBL2679278 0.81 CDK2 (0.42) CDK2CCNA2CCNA1POLBNTRK1
SCHEMBL2678206 0.81 CCNA2 (0.42) CHRNB4CHRNA3LMNACDK2CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173659-B2 Substituted pyrazolo[4,3-C]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-05-08 US disclosed
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-01-22 US disclosed
EP-1968976-A1 SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-09-17 EP disclosed
WO-2007068619-A1 SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors MAP3K3, MAP3K1, MAP3K19 CHRNB4 4245/4885CHRNA3 3906/4885LMNA 3253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.